Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=66 Treatment of Post-SCI Hypotension
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
N/A N=356 Orthostatic Hypotension Treatment on Rehab Unit
Orthostatic Hypotension · Falls
Primary: Orthostatic Hypotension at Discharge — 39; 44 Participants — p=0.6
N/A N=341 Orthostatic Hypotension in Rehabilitation Patients
Hypotension, Orthostatic
Primary: Orthostatic Hypotension at Discharge — 96 participants
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
N/A N=13 Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
Postural Tachycardia Syndrome
Primary: Alldosterone Increase in Response to Adrenocorticotropin Hormone (ACTH). — 52.5; 57.9 nanograms/dL
Phase 2 N=109 Sex Hormones and Orthostatic Tolerance
Orthostatic Intolerance
Primary: Orthostatic Tolerance — 634 mmHg*min
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
Phase 2 N=11 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride
Orthostatic Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure — 98; 97; 102; 87 mmHg
Phase 1 N=28 The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary: Mean Arterial Blood Pressure Change — 14; 10 mmHg
N/A N=20 Nebivolol in the Supine Hypertension of Autonomic Failure
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure During the Night — 154; 162; 157; 158 mm Hg — p=0.036
Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
Phase 2 N=20 Using Mirabegron to Increase BP in Patients With POTS
Postural Orthostatic Tachycardia Syndrome · Chronic Orthostatic Intolerance · Syncope
Primary: Blood Pressure — 101; 107; 64; 68 mmHg
Phase 2 N=85 Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
Intradialytic Hypotension
Primary: Change in Average Mean Arterial Blood Pressure During Hemodialysis — -0.12; 1.95; 1.60 mmHg — p=0.693
N/A N=102 Leg Elevation to Prevent Hypotension During Labor
Hypotension · Labor Complication
Primary: Number of Patients With Maternal Hypotension Requiring Treatment — 6; 11; 48; 27 Participants
Phase 3 N=16 Prevention of Low Blood Pressure in Persons With Tetraplegia
Hypotension · Spinal Cord Injury
Primary: Systolic Blood Pressure During Head-up Tilt — 91.80; 108.10; 112.04; 129.94 mmHg
N/A N=22 Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure — 19; 3 mm Hg
Phase 4 N=24 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Orthostatic Hypotension
Primary: Time to Onset of Syncope/Near Syncope While on Tilt Table — 1105.6; 1626.6 seconds — p=0.0131
Phase 4 N=24 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
N/A N=12 Effect of Exercise in OI
Orthostatic Intolerance · Postural Tachycardia Syndrome
Primary: Maximal Oxygen Consumption Capacity (VO2 Max) — 27.6; 24.5 mL/kg/min
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
N/A N=65 Does Heart Rate Variablity (HRV) Predict Hypotension in Patients Undergoing Cervical Myelopathy Surgery ?
Heart Rate Variability
Primary: Heart Rate Variability (HRV) — 1439; 2191 ms2
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
N/A N=38 Dietary Salt in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Plasma Volume — 2805; 3032; 2362; 2633 mL
N/A N=70 Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants
Hypotension
Primary: Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life — 9; 9 participants
Phase 2 N=384 Furosemide for Accelerated Recovery of Blood Pressure Postpartum
Hypertension, Pregnancy-Induced
Primary: Persistently Elevated Blood Pressures 7 Days Postpartum — 10; 23 Participants — p=0.03